On the second day of listing, Rznomics shares went straight to the upper price limit on the 19th.
As of 9:23 a.m., Rznomics, a corporations developing ribonucleic acid (RNA)-based gene therapies, was at 117,000 won on the KOSDAQ market, up 27,000 won (30%) from the previous trading day. The stock went straight to the upper limit right after the open.
Earlier, Rznomics listed on the KOSDAQ market on the previous day and finished its first transaction at 90,000 won, up 67,500 won (300%) from the offering price. It succeeded in a so-called "ttattabble," rising fourfold from the offering price.
Founded in 2017, Rznomics specializes in RNA-based gene therapies and mainly develops anticancer drugs and treatments for rare intractable diseases.
It has in its pipeline (development products) the gene therapy candidate "RZ-001," which acts on liver cancer and glioblastoma (a type of brain tumor), as well as "RZ-003" and "RZ-004," which respectively target Alzheimer's disease and retinitis pigmentosa.